{
  "docId": "019dd923-622c-750b-8b9b-a077f08347fa",
  "docSlug": "4934d687cb38",
  "documentTitle": "Valeant Pharmaceuticals International (VRX)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2015-10-30 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 25,
  "pageCount": 39,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a quote to contrast the company's public admission of wrongdoing with their internal dismissal of business risk.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-a077f08347fa/25",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-a077f08347fa#slide-25",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Novartis does not believe the settlement will impact their business",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f7-7334-b228-ea5dd33b7d54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "On Oct. 27, 2015, Novartis announced it has reached a settlement in principle with the DOJ in the amount of $390 million\nNovartis acknowledges the seriousness of the alleged conduct\nNovartis states that they intend to continue to use the Specialty Pharmacy channel\nIt is unclear if any new Corporate Integrity Agreement will be put in place, but Novartis does not believe the settlement will impact their business",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e62ec076-7207-42a3-b970-c68d4be06fdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.12,
        "y": 0.64
      },
      "kind": "quote",
      "text": "Novartis said it cannot say much, but it does not expect any problems that would relate to Entresto [newly launching product], nor does it expect any significant impact on other businesses.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "daff28a8-34c9-42d8-a4a6-fdfafd635cba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Novartis said it cannot say much, but it does not expect any problems that would relate to Entresto [newly launching product], nor does it expect any significant impact on other businesses.\" — Bernstein, October 28, 2015",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-70f7-7334-b228-ee553f846e30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.45,
        "y": 0.79
      },
      "kind": "source-note",
      "text": "- Bernstein, October 28, 2015",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f671e7b-4ec8-4880-9730-c11fae7e5b8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.55,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Novartis: A Recent Case Study Implications for Novartis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca316b97-342a-4a0e-9aa6-4468d80730bb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "21a91a5a-6d21-471f-87cb-fa0f71b95e77",
      "evidence": "The slide juxtaposes the admission of serious misconduct with the company's claim of no business impact.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}